AKESF Quote, Financials, Valuation and Earnings

China Pharma Holding has a net margin of -- compared to Akeso's net margin of -69.14%. Akeso's return on equity of -15.02% beat China Pharma Holding's return on equity of -61.79%.

Akeso has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holding has an analysts' consensus of -- which suggests that it could fall by --. Given that Akeso has higher upside potential than China Pharma Holding, analysts believe Akeso is more attractive than China Pharma Holding.

Akeso has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison China Pharma Holding has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.848%.

Akeso has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akeso pays -- of its earnings as a dividend. China Pharma Holding pays out -- of its earnings as a dividend.

Akeso quarterly revenues are --, which are smaller than China Pharma Holding quarterly revenues of $1.1M. Akeso's net income of -- is lower than China Pharma Holding's net income of -$785.6K. Notably, Akeso's price-to-earnings ratio is 18.19x while China Pharma Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akeso is 32.36x versus 0.85x for China Pharma Holding. Usually stocks with elevated PS ratios are considered overvalued.

Summit Therapeutics has a net margin of -- compared to Akeso's net margin of --. Akeso's return on equity of -15.02% beat Summit Therapeutics's return on equity of --.

Akeso has a consensus price target of --, signalling downside risk potential of --. On the other hand Summit Therapeutics has an analysts' consensus of $34.87 which suggests that it could grow by 76.28%. Given that Summit Therapeutics has higher upside potential than Akeso, analysts believe Summit Therapeutics is more attractive than Akeso.

Akeso has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Summit Therapeutics has a beta of -1.058, suggesting its less volatile than the S&P 500 by 205.802%.

Akeso has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Summit Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akeso pays -- of its earnings as a dividend. Summit Therapeutics pays out -- of its earnings as a dividend.

Akeso quarterly revenues are --, which are smaller than Summit Therapeutics quarterly revenues of --. Akeso's net income of -- is lower than Summit Therapeutics's net income of -$62.9M. Notably, Akeso's price-to-earnings ratio is 18.19x while Summit Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akeso is 32.36x versus 15,053.80x for Summit Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech has a net margin of -- compared to Akeso's net margin of --. Akeso's return on equity of -15.02% beat Sinovac Biotech's return on equity of -1.05%.

Akeso has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech has an analysts' consensus of -- which suggests that it could fall by --. Given that Akeso has higher upside potential than Sinovac Biotech, analysts believe Akeso is more attractive than Sinovac Biotech.

Akeso has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sinovac Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Akeso has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Akeso pays -- of its earnings as a dividend. Sinovac Biotech pays out -328.35% of its earnings as a dividend.

Akeso quarterly revenues are --, which are smaller than Sinovac Biotech quarterly revenues of --. Akeso's net income of -- is lower than Sinovac Biotech's net income of --. Notably, Akeso's price-to-earnings ratio is 18.19x while Sinovac Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akeso is 32.36x versus 1.49x for Sinovac Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of -- compared to Akeso's net margin of -45.49%. Akeso's return on equity of -15.02% beat Zai Lab's return on equity of -33.29%.

Akeso has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab has an analysts' consensus of $55.39 which suggests that it could grow by 35.1%. Given that Zai Lab has higher upside potential than Akeso, analysts believe Zai Lab is more attractive than Akeso.

Akeso has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zai Lab has a beta of 0.958, suggesting its less volatile than the S&P 500 by 4.151%.

Akeso has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akeso pays -- of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend.

Akeso quarterly revenues are --, which are smaller than Zai Lab quarterly revenues of $106.5M. Akeso's net income of -- is lower than Zai Lab's net income of -$48.4M. Notably, Akeso's price-to-earnings ratio is 18.19x while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akeso is 32.36x versus 9.96x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.